RNasin Plus RNase Inhibitor or Equivalent
ID: 75N95025Q00036Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAROCKVILLE, MD, 20852, USA

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

LABORATORY EQUIPMENT AND SUPPLIES (6640)

Original Source

https://sam.gov/opp/4371f16c7038441b957f73ea346a8270/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of RNasin Plus RNase Inhibitor or equivalent products for neurodegenerative disease research. The primary objective is to procure reagents that will assist in sequencing small RNA transcripts from Alzheimer’s Disease patient samples, which is crucial for identifying potential therapeutic targets and biomarkers. This procurement is vital for advancing the understanding of gene expression differences in Alzheimer’s Disease, thereby contributing to the overall research efforts in this area. Interested companies must submit their capability statements to Eric McKay at eric.mckay@nih.gov by November 27, 2024, at 4:00 p.m. Eastern Time, with no costs incurred by the government for responses.

    Point(s) of Contact
    ERIC MCKAY
    (301) 480-2406
    eric.mckay@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    RNasin Plus RNase Inhibitor or Equivalent
    Currently viewing
    Sources Sought
    Similar Opportunities
    Sequencing Kits and Accessories for Oxford Nanopore Sequencing Systems
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources to provide sequencing kits and accessories for Oxford Nanopore Sequencing Systems as part of a Sources Sought notice. The primary objective of this procurement is to supply the Center for Alzheimer’s Disease and Related Dementias with essential reagents for neurodegenerative disease research, particularly for long read sequencing aimed at identifying causative genes for conditions like Parkinson’s disease. This initiative is aligned with the Global Parkinson’s Genetics Program (GP2), which aims to genotype over 150,000 volunteers globally to enhance understanding of genetic risk factors. Interested companies must submit their capability statements by November 27, 2024, to Eric McKay at eric.mckay@nih.gov, with the anticipated delivery dates for the supplies spanning from September 30, 2025, to September 30, 2027.
    SOURCES SOUGHT: Long read sequencing services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide long read sequencing services as part of the Global Parkinson’s Genetics Program (GP2). The objective is to genotype over 150,000 individuals worldwide to enhance understanding of genetic risk factors associated with Parkinson’s Disease, requiring the contractor to perform long read sequencing on 500 human genomic DNA samples with a minimum coverage of 25X per sample, alongside ancillary services such as DNA fragmentation, library preparation, and bioinformatics support. Interested parties must submit their capability statements by November 15, 2024, at 9:00 AM Eastern Time, to Rashiid Cummins at rashiid.cummins@nih.gov, ensuring compliance with the specified guidelines and format.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the establishment of the NIH NeuroBioBank Brain and Tissue Repository. The objective of this procurement is to create and manage contract collection sites for acquiring, storing, and distributing human brain and central nervous system tissues for research purposes, aimed at advancing the understanding of nervous system disorders. This initiative is critical for enhancing biomedical research by providing well-characterized specimens to researchers, thereby facilitating studies that could lead to improved treatments and interventions. Proposals are due by November 25, 2024, with the anticipated contract performance period starting on May 1, 2025, and extending potentially through multiple option years. Interested vendors should contact Robin D. Knightly at robin.knightly@nih.gov or call +1 301 827 5302 for further information.
    A--National Gene Vector Biorepository (NGVB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.
    Scientific Management and Support to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (NRGR)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for scientific management and support services for the National Institute of Mental Health Repository and Genomics Resource (NRGR). The objective of this procurement is to sustain, enhance, and enrich the NRGR, which provides critical biospecimens and genomic data for research on psychiatric disorders, thereby facilitating a deeper understanding of the genetic factors involved in mental health. This initiative is vital for advancing both basic and translational research in the field of mental health, ensuring broad access to valuable resources for researchers. Proposals are due by November 21, 2024, and must be submitted electronically via the NIH's eCPS system; interested parties can contact Sarah Adan at sarah.adan@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.
    Science and Health Communication Consulting Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide Science and Health Communication Consulting Services for the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS) Center for Alzheimer’s and Related Dementias (CARD). The primary objective of this procurement is to enhance internal and external communications through various tasks, including the creation of newsletters, scientific manuscript editing, community building initiatives, and the maintenance of the CARD website. This consulting service is crucial for promoting awareness of CARD’s resources and fostering collaboration in Alzheimer’s and related dementias research. Interested contractors must submit their responses by November 21, 2024, to Kevin Alvarez at kevin.alvarez@nih.gov, detailing their capabilities and business size status in accordance with the NAICS code 541690.
    J--NextSeq2000 Maintenance Agreement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Child Health and Development (NICHD), intends to award a non-competitive contract to Illumina, Inc. for a maintenance agreement on the NextSeq2000 sequencing system. This agreement is crucial for ensuring the optimal performance of the sequencer, which is utilized for genetic analyses related to mental health conditions, particularly alcohol use disorder. The maintenance contract will cover preventative maintenance, emergency repairs, and necessary updates from December 24, 2024, to December 23, 2025, with Illumina being the sole provider capable of servicing this specialized equipment. Interested parties may submit their qualifications by November 25, 2024, and for further inquiries, they can contact Jacob M. Balenson at jacob.balenson@nih.gov or call 301-827-8302.
    Rees Scientific Environmental Monitoring System Preventative Maintenance Services.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a follow-on fixed-price contract for preventative maintenance services on the Rees Scientific Environmental Monitoring System. This contract will cover maintenance, inspection, calibration, system and software upgrades, adjustments, and safety checks for a one-year period, ensuring compliance with current Good Manufacturing Practices (cGMP) for facilities involved in manufacturing cellular and gene therapies. The Rees Scientific system is critical for monitoring environmental conditions and equipment performance in these facilities, and only Rees Scientific Corporation, as the original equipment manufacturer, is authorized to perform these services due to the proprietary nature of the equipment. Interested parties must submit capability statements by November 17, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov for consideration.